Gemma Halliday

Jan 15, 2025 | theanalyticalscientist.com | Gemma Halliday |Anup Chugani |Ephrem Chin

Though next-generation sequencing (NGS) technologies have revolutionized cancer genomics by enabling comprehensive analysis of tumor genomes, the complexity of data interpretation poses a challenge for clinical practice. Clinicians, pharmaceutical companies, and companion diagnostics providers must navigate a vast array of genomic alterations, each with varying clinical significance.

May 9, 2024 | thepathologist.com | Gemma Halliday |Anup Chugani |Ephrem Chin

Though next-generation sequencing (NGS) technologies have revolutionized cancer genomics by enabling comprehensive analysis of tumor genomes, the complexity of data interpretation poses a challenge for clinical practice. Clinicians, pharmaceutical companies, and companion diagnostics providers must navigate a vast array of genomic alterations, each with varying clinical significance.